Acer Therapeutics Inc. - FORM 10-K - EX-32.1 - CERTIFICATION - March 15, 2016

Attached files

file filename
EX-4.13 - AMENDED AND RESTATED SERIES N WARRANTS - Acer Therapeutics Inc.ex413.htm
EX-31.2 - CERTIFICATION - Acer Therapeutics Inc.ex_312.htm
EX-23.1 - CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM - Acer Therapeutics Inc.ex_231.htm
EX-31.1 - CERTIFICATION - Acer Therapeutics Inc.ex_311.htm
EX-32.2 - CERTIFICATION - Acer Therapeutics Inc.ex_322.htm
EX-10.21 - AMENDMENT TO STOCK PURCHASE AGREEMENT - Acer Therapeutics Inc.ex_1021.htm
EX-10.22 - OFFER LETTER - Acer Therapeutics Inc.ex_1022.htm
10-K - ANNUAL REPORT - Acer Therapeutics Inc.opxa_10k.htm
EXHIBIT 32.1
 
 
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO SECTION 906
OF THE SARBANES-OXLEY ACT OF 2002
 
In connection with the Annual Report of Opexa Therapeutics, Inc. (the “Company”) on Form 10-K for the period ending December 31, 2015 (the “Report”), as filed with the Securities and Exchange Commission on the date hereof, I, Neil K. Warma, President and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, to the best of my knowledge, that:
 
1.
The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
 
2.
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
 
     
       
Date: March 15, 2016
By:
/s/ Neil K. Warma  
   
Neil K. Warma
  
   
President and Chief Executive Officer
(Principal Executive Officer)
  
       
 
 

Acer Therapeutics Inc. Reports